Twist Bioscience (NASDAQ:TWST) Coverage Initiated by Analysts at Wolfe Research

Wolfe Research started coverage on shares of Twist Bioscience (NASDAQ:TWST) in a report released on Friday, MarketBeat reports. The brokerage issued an outperform rating and a $60.00 price target on the stock.

Other equities research analysts have also issued research reports about the company. Evercore ISI lifted their price objective on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Robert W. Baird raised their price target on Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a report on Tuesday, November 19th. Leerink Partners upped their price objective on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a report on Thursday, October 17th. Barclays reduced their target price on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, November 19th. Finally, TD Cowen restated a “buy” rating and set a $58.00 target price on shares of Twist Bioscience in a research report on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $51.90.

Twist Bioscience Stock Performance

TWST stock opened at $47.50 on Friday. Twist Bioscience has a one year low of $27.41 and a one year high of $60.90. The company has a fifty day moving average of $44.94 and a 200-day moving average of $46.70. The stock has a market capitalization of $2.82 billion, a PE ratio of -13.19 and a beta of 1.82.

Insiders Place Their Bets

In other news, SVP Paula Green sold 860 shares of the stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $52.70, for a total value of $45,322.00. Following the sale, the senior vice president now directly owns 133,715 shares in the company, valued at $7,046,780.50. This represents a 0.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Emily M. Leproust sold 2,216 shares of Twist Bioscience stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $52.70, for a total value of $116,783.20. Following the transaction, the chief executive officer now owns 674,718 shares of the company’s stock, valued at $35,557,638.60. This represents a 0.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 101,787 shares of company stock worth $4,584,508. 3.92% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Twist Bioscience

A number of large investors have recently bought and sold shares of TWST. Wilmington Savings Fund Society FSB acquired a new position in shares of Twist Bioscience in the third quarter worth $34,000. Signaturefd LLC raised its stake in Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after purchasing an additional 306 shares during the last quarter. EdgeRock Capital LLC purchased a new position in Twist Bioscience in the 2nd quarter valued at about $43,000. Blue Trust Inc. lifted its holdings in Twist Bioscience by 2,912.8% in the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after purchasing an additional 1,136 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale acquired a new stake in shares of Twist Bioscience during the 2nd quarter worth about $61,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.